Clinical efficacy report of Linaclotide
Background and overview
Linaclotide (trade name LINZESS) is a new type of GC-C (intestinal epithelial cell uridine cyclase C) receptor agonist developed by Ironwood. It activates the GC-C receptor on the top of intestinal epithelial cells, leading to an increase in intracellular and extracellular cyclic guanosine phosphate. Its effect is to increase the secretion of chlorine and bicarbonate into the intestinal cavity, which leads to increased fluid secretion and accelerated stool. It is used to treat adult patients with slow transit constipation and constipation-type irritable bowel syndrome (IBS-C).
Clinical efficacy report
Wang Wei, Department of Gastroenterology, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, and others discussed the effect and safety of linaclotide combined with compound polyethylene glycol electrolyte powder in bowel preparation before colonoscopy.
Methods: 156 patients who were to undergo colonoscopy in Suzhou Jiulong Hospital, Shanghai Jiaotong University School of Medicine from January to June 2020 were selected as the research objects, and they were divided into control group, observation group A, and observation group by random number table method. B, 52 cases in each group.
Patients in the control group were treated with 3 boxes of compound polyethylene glycol electrolyte powder for intestinal cleansing, patients in the observation group A were treated with linaclotide combined with 2 boxes of compound polyethylene glycol electrolyte powder for intestinal cleansing, and patients in the observation group B were treated with 2 boxes of compound polyethylene glycol.
Electrolytes disperse the intestines.
The intestinal cleanliness and the total incidence of adverse reactions of the three groups of patients were compared.
Results: The scores of left colon, transverse colon, right colon and Boston Bowel Preparation Scale (BBPS) scores of observation group B were lower than those of control group, the difference was statistically significant (P<0.05);
observation group A left Compared with the control group, the scores of semicolon, transverse colon, right colon and BBPS total score were not statistically significant (P>0.05).
The scores of left colon, transverse colon, right colon and BBPS of observation group A were higher than those of observation group B (P<0.05).
The total incidence of adverse reactions in observation group A and B were lower than those of control group, and the difference was statistically significant.
Significance (P<0.05); There was no statistically significant difference in the total incidence of adverse reactions between observation group A and observation group B (P>0.05).
Conclusion: The intestinal preparation method of linaclotide combined with 2 boxes of compound polyethylene glycol electrolyte powder is basically equivalent to the intestinal preparation effect of 3 boxes of compound polyethylene glycol electrolyte powder alone, and can reduce the intestinal preparation process.
The total incidence of adverse reactions of the drug is relatively high in safety. Its intestinal cleansing effect is also better than using 2 boxes of compound polyethylene glycol electrolyte powder alone.